Epista Life Science

Executive Summary

Epista Life Science is a specialized consultancy headquartered in Copenhagen, Denmark, that helps life science companies navigate the complex intersection of business, IT, and regulatory compliance. Founded in 2015, the firm offers strategic and hands-on implementation services across clinical, regulatory, quality, manufacturing, and commercial domains. By addressing operational complexity and digital transformation challenges, Epista enables clients to manage regulatory pressure more effectively. With deep expertise in regulated environments, the company serves as a critical partner for pharmaceutical, biotech, and medical device organizations seeking to streamline processes and maintain compliance in an increasingly stringent regulatory landscape. Despite being a private company with no disclosed funding or valuation, Epista has established a niche position in the European life science consulting market, leveraging its domain knowledge to differentiate from generalist competitors. The company's focus on AI and digital health further positions it to capitalize on growing demand for technology-enabled compliance solutions. In the near term, Epista Life Science is well-positioned to benefit from several tailwinds. The implementation of the EU In Vitro Diagnostic Regulation (IVDR) and Medical Device Regulation (MDR) continues to create compliance challenges for life science companies, driving demand for specialized consultancy services. Additionally, the acceleration of digital transformation in the pharmaceutical industry is pushing companies to invest in AI-driven quality management and regulatory systems. Epista's expertise in both IT and compliance makes it a natural partner for these initiatives. While the company operates in a competitive market, its niche focus and proven track record should support steady organic growth. A conviction score of 65 reflects moderate confidence in the company's ability to execute and capture market share, tempered by the lack of public financial data and the consultancy's reliance on project-based revenue.

Upcoming Catalysts (preview)

• Q3 2026New strategic partnership with a top-tier pharmaceutical company60% success
• Q4 2026Expansion of AI-powered compliance automation platform70% success
• Q2 2027EU IVDR deadline driving surge in consultancy contracts85% success